IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1099
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$36.4B
Tim v. Hauwermeiren
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ARGX ARGENX SE | 56 | 60 | 50 | 58 | 59.4x | - | 60.6% | 53.7% | 89.7% | -3.0% | 37.9% | 76.4% | 0.0% | 1.0x | $36.4B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ARGENX SE (ARGX) receives a "Hold" rating with a composite score of 56.4/100. It ranks #1099 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Tim v. Hauwermeiren
Chief Executive Officer
Labor Force
650
60
27
90
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for ARGX
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ARGX.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 60 | 57 | +3NEUTRAL |
| MOMENTUM | 58 | 49 | +9ALPHA |
| VALUATION | 50 | 29 | +21ALPHA |
| INVESTMENT | 27 | 23 | +4NEUTRAL |
| STABILITY | 90 | 93 | -3NEUTRAL |
| SHORT INT | 33 | 22 | +11ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 60.6% (sector -2.5%)
GM 90% vs sector 43%, OM -3% vs sector 1%
Capital turnover N/A, R&D intensity 44.7%
Rev growth 76%, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns ARGENX SE a Hold rating, with a composite score of 56.4/100 and 3 out of 5 stars. Ranked #1099 of 7,333 stocks, ARGX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 60/100, ARGX shows adequate but unremarkable business quality. The company reports a return on equity of 60.6% (sector avg: -2.5%), gross margins of 89.7% (sector avg: 42.5%), net margins of 37.9% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
ARGX's value score of 50/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 59.36x, a P/B ratio of 9.50x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
ARGENX SE's investment score of 27/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 76.4% vs. a sector average of 5.9% and a return on assets of 53.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ARGX demonstrates moderate momentum with a score of 58/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 76.4% year-over-year, while a beta of 0.43 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
ARGENX SE earns an excellent stability score of 90/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.43 and a debt-to-equity ratio of 1.00x (sector avg: 0.2x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
ARGENX SE's short interest score of 33/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. At $36.4B (large-cap), ARGX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
ARGENX SE is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1099 of 7,333 overall (85th percentile). Key comparisons include ROE of 60.6% exceeding the -2.5% sector median and operating margins of -3.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ARGX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (90) vs Investment (27) — closing this gap could shift the rating.
ROE 2544% BELOW SECTOR MEDIAN
Gross Margin 111% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 335% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate ARGENX SE (ARGX) as a Hold with a composite score of 56.4/100 at a current price of $841.36. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in stability (90th percentile) and quality (60th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (27th percentile) and value (50th percentile) tempers our overall conviction. We assign a Narrow Moat rating (64/100), Low uncertainty, and Exemplary capital allocation.
Key items to watch: sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ARGENX SE holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 56.4/100 places it at rank #1099 in our full 7,333-stock universe. With a $36.4B market capitalization, ARGENX SE operates at meaningful scale within the Manufacturing sector, providing competitive advantages in distribution, procurement, and customer reach.
Revenue is growing at 76%, though momentum at the 58th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 90% (+47.2pp vs sector) narrow to operating margins of -3% (-4.3pp vs sector) and net margins of 37.9%, yielding a gross-to-net conversion rate of 42%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $841.36, ARGENX SE is trading near fair value based on current fundamentals. Our value factor score of 50/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 59.4x (a 167% premium to the sector median of 22.3x), P/B of 9.5x, P/S of 5.9x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis finds only partially justified by current fundamentals.
Gross margins of 90% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 60.6% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 76% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (1% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Return on assets of 53.7% indicates efficient deployment of the full asset base, not just equity capital.
We assign a Low uncertainty rating to ARGENX SE. The company exhibits strong financial stability with a beta of 0.43, conservative leverage (1% D/E), and a stability factor in the 90th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.43 — while defensive, this may indicate limited upside participation in bull markets; elevated valuation multiple (P/E 59.4x) that leaves limited margin for error. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 90th percentile and quality factor at the 60th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 90% provide a buffer against cost pressures; conservative leverage (1% D/E) limits balance sheet risk; above-average stability (90th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate ARGENX SE's capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 60.6%, disciplined leverage (1% D/E), best-in-class net margins of 37.9%. Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — ARGENX SE meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 53.7% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, ARGENX SE receives a Hold rating with a composite score of 56.4/100 (rank #1099 of 7,333). Our quantitative framework assigns a Narrow Moat (64/100, trend: stable), Low uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 57/100.
Our analysis supports a neutral stance on ARGENX SE. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign ARGENX SE a Narrow Moat rating with a composite moat score of 64/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that ARGENX SE can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 15.4/20.
The strongest moat sources are margin superiority (15.4/20) and economic value creation (15/20). GM 90% vs sector 43%, OM -3% vs sector 1%. ROE proxy 60.6% (sector -2.5%). These pillars form the core of ARGENX SE's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (8.1/20) and growth durability (11.4/20). Interest coverage N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ARGENX SE's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 90% providing a solid profitability foundation, robust top-line growth of 76% expanding the revenue base, returns on equity of 60.6% driving shareholder value creation. The margin cascade from 90% gross to -3% operating to 37.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 60th percentile.
The margin profile shows gross margins of 90%, operating margins of -3%, net margins of 37.9%. Return metrics include ROE of 60.6% and ROA of 53.7%. Relative to the Manufacturing sector, gross margins are 47.2 percentage points above the sector median of 43%, and ROE of 60.6% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 1%, revenue growth of 76%. The sector median D/E is 0%, putting ARGENX SE at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
A P/E of 59.4x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
Above 50MA
37.18%
Net New Highs
+51081

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. US equities […]
A recap and analysis of a stock-picker's week is followed by our strategy note. We include a few stocks and ETFs that could be considered buying opportunities to implement strategies of two prevalent trends: Rotation to Value and Sell America.

Argenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.